Company intelligence

NRIX

Nurix Therapeutics, Inc. · NASDAQ · Healthcare

Price$25.34-0.67% · −$0.17

Market cap2.77BEquity value

P / E-7.3Trailing ratio

Volume1.91MLatest session

Market data

NRIX price chart

TradingView

Related signals

1 min delayed

Browse public NRIX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NRIXJun 8, 2026+6.83% since signal

Roche-Nurix alliance on NX-5948 boosts NRIX with upfront cash and milestones

Roche and Nurix formed an exclusive license to co-develop bexobrutideg (NX-5948), a BTK degrader. Nurix receives $700M upfront and could earn up to $2.3B in milestones, with shared development costs and US co-commercialization. The deal de-risks NX-5948's path and may accelerate its Phase 3 in CLL, potentially lifting NRIX's valuation in the near term.

View signal analysis

NRIXJul 25, 2024+1.72% since signal

How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%

NRIX shares gained 3.1% recently, closing at $21.09. Analysts estimate a mean price target of $26.42, suggesting 25.3% upside. Positive earnings estimate revisions strengthen the case for a stock surge. NRIX has a Zacks Rank #2 (Buy), indicating strong performance potential. Analyst agreement on price targets means potential for significant stock movement.

View signal analysis

Research